

March 27, 2018



Boston Therapeutics Creates New Scientific Advisory Board

Strategic Medical Advisory with Relevant Pharmaceutical Guidance is Added to Expand the Strategic Development

LAWRENCE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, an innovator in the design, development and early commercialization of novel therapeutics for the potential treatment of diabetes and related complications, is pleased to announce the addition of three accomplished and well credentialed scientists and clinicians to its newly created Scientific Advisory Board. The company is actively establishing clinical roadmaps for their patented investigative compounds in the US, Europe and Asia. The Company is very appreciative to have these first three experts engaged to provide the best strategic advice for the management and shareholders. Additional biographical information can be found for the new advisors at <https://www.bostonti.com/about-bti/advisors.html>

John Amatruda, MD, FACE is an Adjunct Professor of Medicine, Endocrinology at **Yale University**, Former Senior Vice President & Franchise Head, Diabetes & Obesity, **Merck & Co., Inc.** and former Vice President, Therapeutic Area Research Head, Metabolic Disorders Research, **Bayer Corp.** Dr. Amatruda has a deep developmental knowledge of the mechanisms of action related to the Boston Therapeutics clinical candidates.

Makaranda Jawadekar, Ph.D is Former **Pfizer**, Worldwide BioPharmaceutical Businesses, Portfolio Management and Analytics, as well as R & D, External Alliance Management, Contracting, Outsourcing, Benchmarking, Drug Delivery Systems assessment, Formulations, Clinical Supply Mfg and Packaging, CTM, Pharmaceuticals, Pharm Sciences, Performance Metrics evaluations and assessment, Asia R & D. Dr. Jawadekar has broad experience in pharmaceuticals and extensive networks in the US, EU, India and other parts of Asia including Japan and China.

Richard Pittner, PhD is former **Amylin**, Senior Director and Head of Discovery Biology, Former **Eli Lilly and Company** Senior Director and Head Global External Research & Development (GERD), Bio-Medicines Business Unit, Former **Pfizer** Senior Director and Head External R&D Innovation (ERDI) Head for Cardiovascular Metabolic and Entero/Endocrine Disease (CVMED). Dr. Pittner is uniquely suited to advise in the area of peptide design, manufacturing formulation and development.

Boston Therapeutics CEO Carl Rausch stated, "We are pleased to have these industry experts join our new and expanding group of supporters as we progress the technology and expand the technology footprint. Experienced insight and guidance will drive our technology and its output to worldwide commercialization." The scientific advisory board will convene quarterly and operate through advanced media communications as needed.

About Boston Therapeutics, Inc. www.bostonti.com

Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) and with an office in Albuquerque, NM is an innovator in design, development and commercialization of compounds to treat diabetes and diabetes related complications.

Forward Looking Statement

This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," "expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

Contact: Boston Therapeutics, Inc.
Loraine Upham, COO
Phone: 603-935-9799
Email: loraine.upham@bostonti.com
www.bostonti.com

Source: Boston Therapeutics, Inc.